Sorafenib (Compound)

Synonyms:Sorafenib, 284461-73-0, Nexavar, BAY 43-9006, sorafenibum, 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide, 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE, Sorafenib free base, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide, 100012-18-8

Pubchem:PUBCHEM:216239

Id:0f1381ed-87d2-5989-a625-810bf435625c

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Sorafenib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Sorafenib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Sorafenib.

Results found

Linked to

	Label	Description
	BRD-K23984367-001-07-5 Substance (Entity type)	A Substance
	KU-C104227 in similarity relationship with Sorafenib Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Sorafenib in similarity relationship with Ro-28-1675 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Sorafenib bioactivity Receptor-type tyrosine-protein kinase FLT3 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	Sorafenib bioactivity Mitogen-activated protein kinase 14 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	oligomycin-a in similarity relationship with Sorafenib Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Sorafenib indication Renal Cell Carcinoma Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	Sorafenib negatively regulates SQLE Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Sorafenib negatively regulates SC5D Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Sorafenib negatively regulates MSMO1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS

BRD-K23984367-001-07-5

Substance (Entity type)

A Substance

KU-C104227 in similarity relationship with Sorafenib

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from LINCS

Sorafenib in similarity relationship with Ro-28-1675

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from LINCS

Sorafenib bioactivity Receptor-type tyrosine-protein kinase FLT3

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Sorafenib bioactivity Mitogen-activated protein kinase 14

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

oligomycin-a in similarity relationship with Sorafenib

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from LINCS

Sorafenib indication Renal Cell Carcinoma

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Sorafenib negatively regulates SQLE

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from LINCS

Sorafenib negatively regulates SC5D

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from LINCS

Sorafenib negatively regulates MSMO1

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.